Instructions to Authors 2013

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice):
1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinasios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2013 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
General Policy

• IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.

• One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

• IN VIVO supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Selection of Recent Articles

Proteomic Profiling to Identify Prognostic Biomarkers in Heart Failure. P.A. SCOTT, B. ZEIDAN, L.L. NG, M. ZEB, J.A. ROSENGARTEN, S. GARBI, N.P. CURZEN, J.M. MORGAN, P.A. TOWNSEND (Southampton; Leicester, UK; Athens, Greece)

Diverging In Vitro Antibody Isotype Switching Preference in B-Lymphocytes from C57BL/6 and FVB Mice. A.G. PUTHIYAVEETIL, B. OKYERE, C.M. REILLY, D. CAUDELL (Blacksburg, VA, USA)

The Zebrafish - Danio rerio - Is a Useful Model for Measuring the Effects of Small-molecule Mitigators of Late Effects of Ionizing Irradiation. M.W. EPPERLY, N. BAHARY, M. QUADER, V. DEWALD, J.S. GREENBERGER (Pittsburgh, PA, USA)

Breast Cancer: Mechanisms Involved in Action of Phytoestrogens and Epigenetic Changes. A. DAGDEMIR, J. DURIF, M. NGOLLO, Y.-J. BIGNON, D. BERNARD-GALLON (Clermont-Ferrand, France)


In Vivo Models for Defining Molecular Subtypes of the Primitive Neuroectodermal Tumor Genome: Current Challenges and Solutions. J.D. LARSON, D.A. LARGAESPAD (Minneapolis, MN, USA)

Effects of Minocycline on Hematopoietic Recovery After Whole-body Irradiation. S. MEHROTRA, M.J. PECAUT, D.S. GRIDLEY (Loma Linda, CA, USA)

Sequential Changes in the Expression of Wnt- and Notch-related Genes in the Vagina and Uterus of Ovariectomized Mice after Estrogen Exposure. T. NAKAMURA, S. MIYAGAWA, Y. KATSU, T. SATO, T. IGUCHI, Y. OHTA (Yamagata; Okazaki; Sapporo; Yokohama; Tottori, Japan)

Catecholamines Reduce Dose-dependent Oedema Formation and Inflammatory Reaction in an Isolated Rat Lung Model. C. DACHO, A. DACHO, A. GEISSLER, C. HAUSER, K. NOWAK, G. BECK (Heidelberg; Essen; Wiesbaden, Germany)

Biocompatibility of Membranes with Unrestricted Somatic Stem Cells. C. NAUJOKS, F.P. VON BECK, F. LANGEMANN, K. KÜBLER, J. HANDSCH (Düsseldorf, Germany)


Acclimatization of Mice to Different Cage Types and Social Groupings with Respect to Fecal Secretion of IgA and Corticosterone Metabolites. C.J. BUNDGAARD, O. KALLIKOSKI, K.S. ABELSON, J. HAU (Copenhagen, Denmark)

Exploring Anticarcinogenic Agents in a Rat Hepatocarcinogenesis Model – Focus on Selenium and Statins. L. BJÖRKHEM-BERGMAN, L. EKSTRÖM, L.C. ERIKSSON (Stockholm, Sweden)


Amino Acid Chloramine Damage to Proliferating Cell Nuclear Antigen in Mammalian Cells. S.A. SALAMA, R.M. SNAPKA (Columbus, OH, USA; Cairo, Egypt)

The Effect of Insulin-like Growth Factor II in the Regulation of Tumour Cell Growth In Vitro and Tumourigenesis In Vivo. M. HALJÉ, M. NORDIN, D. BERGMAN, W. ENGSTRÖM (Uppsala, Sweden)
Histological Inflammatory Cell Infiltration Is Associated with the Number of Lymph Nodes Retrieved in Colorectal Cancer. Y.W. KIM, K.M. JAN, D.H. JUNG, M.Y. CHO, N.K. KIM (Wonju; Seoul, Republic of Korea)................................................................................................................................. 5143

Ethnic Variation in Toxicity and Outcome of Adjuvant Chemoradiation for Gastric Cancer in Israel. R.M. BRENNER, S. KIVITY, Y. KUNDEI, O. PURIM, N. PELED, E. IDELEVICH, K. LAVRENKOVA, S. KOVEL, E. FENIG, A. SULKES, B. BRENNER (Holon; Petach-Tiqva; Tel-Hashomer; Rehovot; Beer Sheva; Zerifin; Ramat-Aviv; Jerusalem, Israel).................................................................................................................... 5151

A9 Region in EPHB2 Mutation Is Frequent in Tumors with Microsatellite Instability. Analysis of Prognosis. S. RAFAEL, M. VIDARGUERA, S. VEGANZONES, V. DE LA ORDEN, B. MEDIERO, M.L. GUTIERREZ, M.L. MAESTRO (Madrid; Leon, Spain).............................................................................................................................. 5159


A Survey of c-MET Expression and Amplification in 287 Patients with Hepatocellular Carcinoma. S.J. LEE, J. LEE, I. SOHN, M. MAO, W. KAI, C.-K. PARK, H.Y. LIM (Seoul, Republic of Korea; San Diego, CA, USA) .......................................................................................................................... 5179

Chemoradiation as a Definitive Treatment for Cervical Lymph Node Metastases from Unknown Primary Cancer. H. KAIZU, I. OGINO, M. HATA, M.S. OBA, O. SHIONO, M. KOMATSU, T. INOUE (Yokohama, Japan)............................................................................................................................... 5187

Outcome Analysis of 18F-Fluorodeoxyglucose Positron–Emission Tomography in Patients with Lung Cancer After Partial Volume Correction. K. OHTAKA, Y. HIDA, K. KAGA, S. OKAMOTO, T. SHIGA, N. TAMAKI, J. MUTO, R. NAKADA-KUBOTA, S. HIRANO, Y. MATSUI (Sapporo, Japan) ............................................................................................................................ 5193

Aberrant Methylation of the Ras-related Associated with Diabetes Gene in Human Primary Esophageal Cancer. Z. JIN, X. FENG, Q. JIAN, Y. CHENG, Y. GAO, X. ZHANG, L. WANG, Y. ZHANG, W. HUANG, X. FAN, S. CHEN, H. YU, Z. ZHAO, M. DONG, J. LIU, Y. MORI, S.J. MELTZER (Guangdong; Shenzhen, China; Baltimore, MD, USA) .............................................................................................................................. 5199


Errata ....................................................................................................................................................... 5211
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>C-Reactive Protein Is a Negative Independent Factor in Patients with Stage IV Colorectal Cancer Undergoing Oxaliplatin-based Chemotherapy.</td>
<td>M. FUKUCHI, K. KUWABARA, Y. TSUI, H. BABA, K. ISHIBASHI, N. CHIKA, S. HATANO, T. MATSUZAWA, K. KUMAMOTO, Y. KUMAGAI, E. MOCHIKI, H. ISHIDA (Saitama, Japan)</td>
<td>5051</td>
</tr>
<tr>
<td>Clinical Outcomes After First-line EGFR Inhibitor Treatment for Patients with NSCLC, EGFR Mutation, and Poor Performance Status.</td>
<td>Y. OKUMA, Y. HOSONI, M. NAGAMATA, Y. YAMADA, K. SEKIHARA, K. KATO, T. HISHIMA, T. OKAMURA (Tokyo, Japan)</td>
<td>5057</td>
</tr>
<tr>
<td>C-Reactive Protein as Predictor of Recurrence in Patients with Rectal Cancer Undergoing Chemoradiotherapy Followed by Surgery.</td>
<td>Y. TOIYAMA, Y. INOUE, S. SAIGUSA, M. KAWAMURA, A. KAWAMOTO, Y. OKUGAWA, J. HIRO, K. TANAKA, Y. MOHRI, M. KUSUNOKI (Mie, Japan)</td>
<td>5065</td>
</tr>
<tr>
<td>A New β-Tricalcium Phosphate with Uniform Triple Superporous Structure as a Filling Material After Curettage of Bone Tumor.</td>
<td>S. SETO, K. MURAMATSU, T. HASHIMOTO, Y. TOMINAGA, T. TAGUCHI (Ube, Yamaguchi, Japan)</td>
<td>5075</td>
</tr>
<tr>
<td>Clinical Significance of Erlotinib Monotherapy for Gefitinib-resistant Non-small Cell Lung Cancer with EGFR Mutations.</td>
<td>N. KOYAMA, Y. UCHIDA (Saitama, Japan)</td>
<td>5083</td>
</tr>
<tr>
<td>The E-Cadherin Expression vs. Tumor Cell Proliferation Paradox in Endometrial Cancer.</td>
<td>I. GONZÁLEZ-RODILLA, L. ALLER, J. LLORCA, A.-B. MUÑOZ, V. VERNA, J. ESTÉVEZ, J. SCHNEIDER (Santander, Spain)</td>
<td>5091</td>
</tr>
<tr>
<td>Clinical Significance of Total Colonoscopy for Screening of Colon Lesions in Patients with Esophageal Cancer.</td>
<td>T. MIYAZAKI, N. TANAKA, A. SANO, S. SUZUKI, M. SAKAI, T. YOKOBORI, T. INOSE, M. SOHDA, M. NAKAJIMA, M. FUKUCHI, H. OJIMA, H. KATO, H. KUWANO (Gunma; Tochigi, Japan)</td>
<td>5113</td>
</tr>
</tbody>
</table>
The Feasibility and Efficacy of Stereotactic Body Radiotherapy for Centrally-located Lung Tumors. W. TAKAHASHI, H. YAMASHITA, M. OMORI, M. KITAGUCHI, S. SHIBATA-KOBAYASHI, A. SAKUMI, K. NAKAGAWA (Tokyo, Japan) ................................................................. 4959

The E3 Ubiquitin Ligase SIAH2 Is a Prosurvival Factor Overexpressed in Oral Cancer. S.-C. HSIEH, S.-N. KUO, Y.-H. ZHENG, M.-H. TSAI, Y.-S. LIN, J.-H. LIN (Taipei; Tainan; Taichung, Taiwan, ROC) ........... 4965


Improved Survival of Baby Boomer Women with Early-stage Uterine Cancer: A Surveillance, Epidemiology and End Results (SEER) Study. M.A. ELSHAIKH, J. RUTERBUSCH, M.L. COTE, R. CATTANEO II, A.R. MUNKARAH (Detroit, MI, USA) .......... 4983

Radiation Therapy for Stage IVA Cervical Cancer. N. MURAKAMI, T. KASAMATSU, M. MOROTA, M. SUMI, K. INABA, Y. ITO, J. ITAMI (Tokyo, Japan) ................................................................. 4989

Predicting Skin Toxicity According to EGFR Polymorphisms in Patients with Colorectal Cancer Receiving Antibody Against EGFR. R. SAITO, H. SUZUKI, T. YAMADA, S. ENDO, T. MORIWAKI, T. UENO, M. HIROSE, S. HIRAI, K. YAMATO, Y. MIZOKAMI, I. HYODO (Tsukuba, Ibaraki, Japan) .............. 4995

A Retrospective Analysis of Two Different Sequences of Therapy Lines for Advanced Kidney Cancer. C. PAGLINO, G. PROCOPIO, R. SABBATINI, J. BELLMUNT, M. SCHMIDINGER, A. BEARZ, A. BAMIAS, B. MELICHAR, I. IMARISIO, C. TINELLI, C. PORTA (Pavia; Milan; Modena; Aviano, Italy; Barcelona, Spain; Vienna, Austria; Athens, Greece; Olomouc, Czech Republic) ...................... 4999

A Novel Postoperative Inflammatory Score Predicts Postoperative Pancreatic Fistula After Pancreatic Resection. Y. FUJIWARA, T. MISAWA, H. SHIBA, Y. SHIRAI, R. IWASE, K. HARUKI, K. FURUKAWA, Y. FUTAGAWA, K. YANAGA (Tokyo, Japan) ................................................................. 5005


Contents continued on the preceding page
Differential Expression and Prognostic Role of Selected Genes in Colorectal Cancer Patients. P. PITULE, O. VYCTALI, J. BRUHA, P. NOVAK, P. HOSEK, V. TRESKA, I. HLAVATA, P. SOUCEK, M. KRALICKOVA, V. LISKA (Pilsen; Kladno; Prague, Czech Republic) .......................................................... 4855


Synergistic Anti-leukemic Effects of CK2 Inhibitors and Pentabromobenzylisothioureas In Vitro. M. KORONKIEWICZ, Z. CHILMONCZYK, ZYGMUNT KAZIMIERCZUK (Warsaw, Poland) .......................................................... 4891

Calcitonin-induced NF-κB Activation Up-regulates Fibronectin Expression in MG63 Osteosarcoma Cells. I. TSAGARAKI, C. PHENEKOS, E. TSILIBARY, A. TZINIA (Athens, Greece) .......................................................... 4901


Targeting Biliverdin Reductase Overcomes Multidrug Resistance in Leukemia HL60 Cells. S.S. KIM, S. SEONG, S.H. LIM, S.Y. KIM (Seoul, Republic of Korea; Beijing, China) .......................................................... 4913

Clinical Studies


Electrocardiography Changes During Adjuvant Breast Cancer Therapy: Incidence and Risk Factors. A. ELME, T. SAARTO, K.J. TÖTTERMAN, M. UTRIANEN, H. KAUTIAINEN, S. JÄRVENPÄÄ, M. TENHUEN, C. BLOMQVIST (Helsinki; Jyväskylä; Äänekoski, Finland) .......................................................... 4927

Bi-weekly Paclitaxel and Capecitabine as a Second- or Third-line Treatment for Advanced Breast Cancer: A Pilot Study. P.-L. KELLOKUMPU-LEHTINEN, T. TUUNANEN, A.-L. KAUTIO, I. LEHTINEN, M. TANNER (Tampere, Finland) .......................................................... 4933

Detection of Cytomegalovirus DNA in Colorectal Tissue from Swedish and Vietnamese Patients with Colorectal Cancer. J. DIMBERG, T.T. HONG, M. SKARSTEDT, S. LÖFGREN, N. ZAR, A. MATUSSEK (Jönköping, Sweden; Hanoi, Vietnam) .......................................................... 4941

Gut Peptide Profile and Chemotherapy-associated Dyspepsia Syndrome in Patients with Breast Cancer Undergoing FEC60 Chemotherapy. G. RIEZZO, C. CLEMENTE, M. LINSALATA, B. D’ATTOMA, A. ORLANDO, G. CAMPANELLA, F. GIOTTA, F. RUSSO (Bari, Italy) .......................................................... 4947

Chemoprevention of Oral Cancer by Lyophilized Strawberries. B.C. CASTO, T.J. KNOBLOCH, R.L. GALIOTO, Z. YU, B.T. ACCURSO, B.M. WARNER (Columbus, OH, USA) .......................................................... 4757

Chemoprevention with Acetylsalicylic Acid, Vitamin D and Calcium Reduces Risk of Carcinogen-induced Lung Tumors. HANS-CHRISTIAN POMMERGAARD, JAKOB BURCHARTH, J. ROSENBERG, HANS RASKOV (Herlev; Frederiksberg, Denmark) .......................................................... 4767

ID3 Mutations Are Recurrent Events in Double-hit B-Cell Lymphomas. N. GEBAUER, V. BERNARD, A.C. FELLER, H. MERZ (Luebeck, Germany) ...................................................................................... 4771


MCP-1 Promotes Invasion and Adhesion of Human Ovarian Cancer Cells. S. FURUKAWA, S. SOEDA, Y. KIKO, O. SUZUKI, Y. HASHIMOTO, T. WATANABE, H. NISHIYAMA, K. TASAKI, H. HOJO, M. ABE, K. FUJIMORI (Fukushima City, Fukushima, Japan) ........................................................................... 4785

Impact of Interleukin-10 on Phenotype and Gene Expression During Early Monocyte Differentiation into Dendritic Cells. A.M. SCHWARZ, U. BANNING-EICHENSEER, K. SEIDEL, C. MAUZ-KÖRHOLZ, D. KÖRHOLZ, M.S. STAEGE (Leipzig; Halle, Germany) ............................................................................................... 4791

Therapeutic Efficacy for Hepatocellular Carcinoma by Boric Acidmediated Boron Neutron Capture Therapy in a Rat Model. S.-Y. LIN, C.-J. LIN, J.-W. LIAO, J.-J. PEIR, W.-L. CHEN, C.-W. CHI, Y.-C. LIN, Y.-M. LIU, F.-I. CHOU (Hsinchu; Taichung; Taipei, Taiwan, ROC) ........................................................................... 4799


Human Pancreatic Cancer Cells with Acquired Gemcitabine Resistance Exhibit Significant Up-regulation of Peroxiredoxin-2 Compared to Sensitive Parental Cells. S. SUENAGA, Y. KURAMITSU, Y. WANG, B. BARON, T. KITAGAWA, J. AKADA, K. TOKUDA, S. KAINO, S.-I. MAEHARA, Y. MAEHARA, I. SAKaida, K. NAKamura (Ube, Yamaguchi; Fukuoka, Fukuoka, Japan) ........................................................................................................ 4821

Effect of Hyperbaric Oxygenation and Gemcitabine on Apoptosis of Pancreatic Ductal Tumor Cells In Vitro. G. BOSCO, L. GUIZZON, Z. YANG, E. CAMPORESI, A. CASAROTTO, C. BOSIO, D. MANGAR, C. CHEN, M. CANNATO, L. TONILO, G. GARETTO, E. NASOLE, C. BASSI (Padova; Verona, Italy; Syracuse, NY; Tampa, FL, USA) ........................................................................................................ 4827

DNA Methylation of MAPK Signal-inhibiting Genes in Papillary Thyroid Carcinoma. E.K. LEE, K.-W. CHUNG, S.K. YANG, M.J. PARK, H.S. MIN, S.W. KIM, H.S. KANG (Goyang; Seoul, Republic of Korea) .......................................................... 4833

DNA Methylation of MAPK Signal-inhibiting Genes in Papillary Thyroid Carcinoma. E.K. LEE, K.-W. CHUNG, S.K. YANG, M.J. PARK, H.S. MIN, S.W. KIM, H.S. KANG (Goyang; Seoul, Republic of Korea) .......................................................... 4833

Protein-bound Polysaccharide K Reduced the Invasive Ability of Colon Cancer Cell Lines. S. UWAFUI, T. GOI, T. NARUSE, H. KUREBAYASHI, T. NAKAZAWA, Y. HIrono, A. YAMAGUCHI (Fukuoka, Japan) ........................................................................................................ 4841

Anticancer Activity of a Hydrogel Containing Folic Acid Towards MCF-7 and MDA-MB-231 Cells. S. TROMBINO, T. FERRARELLI, M. PELLEGRINO, E. RICCHIO, L. MAURO, S. ANDÔ, N. PICCI, R. CASSANO (Cosenza, Italy) ........................................................................................................ 4847